Ubiquigent and University of Glasgow to collaborate on drug discovery
Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new…
Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new…
The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has issued a call for…
Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of childhood muscular dystrophy…
Researchers at Nagoya University in Japan have identified a novel genetic variant found in some…
Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT…
By measuring immune cells in the cerebrospinal fluid when diagnosing ALS, it is possible to…
FundaMental Pharma GmbH, a preclinical neuroscience company spun out of Heidelberg University in Germany, has…
3P BioPharmaceuticals and BrainEver are to collaborate on developing hEng1, a recombinant homeoprotein, to treat…
Protein misfolding underlies many incurable conditions such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).…
NRG Therapeutics, Ltd. has closed a £16 million ($18.2 million) series A financing. The funding…
German company, Centogene N.V., today (November 4) announced its launch of Biodata Network, a portfolio…
Cell products providing a scalable source of human cells can now help scientists study neurogenerative…